IMMUNOBIOLOGY OF CUTANEOUS T CELL LYMPHOMA

皮肤T细胞淋巴瘤（CTCL）是一种T淋巴细胞恶性肿瘤， 具有辅助性T细胞的功能和表型特性。 这 肿瘤的发病率接近，并可能超过， 何杰金氏病，并定期提出与皮肤病变。 自然 疾病的过程涉及亚克隆的进化， 低分化的T细胞对表皮的亲和力降低 以及广泛传播的倾向增加，导致中位数 从组织病理学诊断起生存期少于5年。 这些研究有两个广泛的相互关联的目标。 首先，两个 单克隆抗体（BE 1和BE 2），其对 CTCL细胞的肿瘤相关抗原，将被研究，以 确定它们作为诊断和潜在治疗的功效 试剂 CTCL抗原与这些和其他单克隆抗体一起， 抗体反应将在功能上和化学上表征为 确定它们与其他已知膜标记物的关系，以及 人类T淋巴瘤病毒是一种疑似致病因子 疾病 第二，表皮的环境 为恶性和良性肿瘤的克隆扩张提供了一个特殊的场所， 辅助性T细胞将被探索。 在这种情况下， 之间，和化学性质，两个因素产生的表皮 细胞（白细胞介素-1样和胸腺生成素样因子）将被 研究了 预计这些研究将有助于更好地 了解，更有效的诊断，并改善CTCL的治疗， 它们也将极大地帮助我们了解 人类T细胞生物学。 （密歇根州）

Cutaneous T-cell lymphoma (CTCL) is a malignancy of T lymphocytes, which have the functional and phenotypic properties of helper T cells. This neoplasm has an incidence approximating, and probably exceeding, that of Hodgkin's disease and regularly presents with skin lesions. The natural course of the disease involves evolution of subclones composed of more poorly differentiated T cells that have a decreased affinity for epidermis and an increased propensity to disseminate widely, leading to a median survival of less than 5 years from the time of histopathological diagnosis. These studies have two broad interrelated objectives. First, two monoclonal antibodies (BE1 and BE2), which have specificity for tumor-associated antigens of CTCL cells, will be studied in order to determine their efficacy as diagnostic and potentially therapeutic reagents. The CTCL antigens with which these and other monoclonal antibodies react will be functionally and chemically characterized to determine their relationship to other known membrane markers, as well as to human T lymphoma virus that is a suspected etiological agent for this disease. Second, the possibility that the environment of the epidermis provides a privileged site for the clonal expansion of malignant and benign helper T cells will be explored. In this context, the relationship between, and chemical properties of, two factors produced by epidermal cells (interleukin-1-like and thymopoietin-like factors) will be investigated. It is anticipated that these studies will facilitate better understanding, more efficient diagnosis, and improved therapy of CTCL and that they will also significantly contribute to our knowledge of basic human T-cell biology. (MI)